BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11294379)

  • 1. 2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.
    Trotter BW; Quigley AG; Lumma WC; Sisko JT; Walsh ES; Hamann CS; Robinson RG; Bhimnathwala H; Kolodin DG; Zheng W; Buser CA; Huber HE; Lobell RB; Kohl NE; Williams TM; Graham SL; Dinsmore CJ
    Bioorg Med Chem Lett; 2001 Apr; 11(7):865-9. PubMed ID: 11294379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From pure FPP to mixed FPP and CAAX competitive inhibitors of farnesyl protein transferase.
    Lannuzel M; Lamothe M; Schambel P; EtiƩvant C; Hill B; Perez M
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1459-62. PubMed ID: 12668012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of a novel series of farnesyl protein transferase inhibitors as non-peptidic CAAX tetrapeptide analogues.
    Perez M; Maraval C; Dumond S; Lamothe M; Schambel P; EtiƩvant C; Hill B
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1455-8. PubMed ID: 12668011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids.
    Hohl RJ; Lewis KA; Cermak DM; Wiemer DF
    Lipids; 1998 Jan; 33(1):39-46. PubMed ID: 9470172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
    deSolms SJ; Ciccarone TM; MacTough SC; Shaw AW; Buser CA; Ellis-Hutchings M; Fernandes C; Hamilton KA; Huber HE; Kohl NE; Lobell RB; Robinson RG; Tsou NN; Walsh ES; Graham SL; Beese LS; Taylor JS
    J Med Chem; 2003 Jul; 46(14):2973-84. PubMed ID: 12825937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.
    Whyte DB; Kirschmeier P; Hockenberry TN; Nunez-Oliva I; James L; Catino JJ; Bishop WR; Pai JK
    J Biol Chem; 1997 May; 272(22):14459-64. PubMed ID: 9162087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics.
    Cohen LH; Pieterman E; van Leeuwen RE; Overhand M; Burm BE; van der Marel GA; van Boom JH
    Biochem Pharmacol; 2000 Oct; 60(8):1061-8. PubMed ID: 11007942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
    J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
    O'Meara SJ; Kinsella BT
    Biochem J; 2005 Feb; 386(Pt 1):177-89. PubMed ID: 15469414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
    Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
    Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photoaffinity labeling of yeast farnesyl protein transferase and enzymatic synthesis of a Ras protein incorporating a photoactive isoprenoid.
    Edelstein RL; Distefano MD
    Biochem Biophys Res Commun; 1997 Jun; 235(2):377-82. PubMed ID: 9199201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
    Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM
    Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
    Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
    Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
    Adjei AA
    Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
    Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.
    Nagase T; Kawata S; Tamura S; Matsuda Y; Inui Y; Yamasaki E; Ishiguro H; Ito T; Miyagawa J; Mitsui H; Yamamoto K; Kinoshita M; Matsuzawa Y
    Br J Cancer; 1997; 76(8):1001-10. PubMed ID: 9376258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.
    Vasudevan A; Qian Y; Vogt A; Blaskovich MA; Ohkanda J; Sebti SM; Hamilton AD
    J Med Chem; 1999 Apr; 42(8):1333-40. PubMed ID: 10212118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases.
    Tucker TJ; Abrams MT; Buser CA; Davide JP; Ellis-Hutchings M; Fernandes C; Gibbs JB; Graham SL; Hartman GD; Huber HE; Liu D; Lobell RB; Lumma WC; Robinson RG; Sisko JT; Smith AM
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2027-30. PubMed ID: 12113834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.